Methods of treating her2-positive cancer
AssigneeGenentech, Inc.
InventorsStephen Chui, Melanie Smitt, Monika Patre
Life of this patent
Estimating the term…
Abstract
Methods of treating patients having HER2-positive cancer are provided. Certain methods involve treatment of HER2 positive breast cancer using a programmed cell death protein 1 (PD-1) binding antagonist or a programmed death ligand 1 (PD-L1) binding antagonist in combination with trastuzumab and pertuzumab or with trastuzumab emtansine. The treatment regimen may be used in various clinical settings, for example, for treatment in the neoadjuvant or metastatic setting.
Claims23
A method of treating HER2 positive breast cancer, the method comprising administering to a patient having said breast cancer a therapeutically effective amount of a programmed cell death protein 1 (PD-1) binding antagonist or a programmed death ligand 1 (PD-L1) binding antagonist in combination with trastuzumab and pertuzumab.
3-4. (canceled)
(canceled)
A method of treating HER2 positive breast cancer, the method comprising administering to a patient having said breast cancer a therapeutically effective amount of programmed cell death protein 1 (PD-1) binding antagonist or a programmed death ligand 1 (PD-L1) binding antagonist in combination with trastuzumab emtansine.
-52. (canceled)
Dependencies are inferred from the claim text.